Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXS NASDAQ:GERN NASDAQ:IRWD NASDAQ:RIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXSCodexis$2.66+7.7%$2.55$0.96▼$3.87$224.51M2.5836,329 shs807,542 shsGERNGeron$1.44+5.9%$1.31$1.04▼$2.01$872.47M0.614.06 million shs11.31 million shsIRWDIronwood Pharmaceuticals$4.38+1.2%$3.84$0.67▼$5.78$706.04M0.22.27 million shs2.99 million shsRIGLRigel Pharmaceuticals$40.26+4.0%$31.74$18.24▼$52.24$716.40M1.14346,095 shs378,419 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXSCodexis+7.69%+14.16%+3.91%+34.34%-3.62%GERNGeron+5.88%+10.77%+23.08%-17.24%+1.05%IRWDIronwood Pharmaceuticals+1.15%+1.86%+32.33%+26.59%+491.89%RIGLRigel Pharmaceuticals+3.98%+3.13%+34.51%+40.13%+112.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXSCodexis$2.66+7.7%$2.55$0.96▼$3.87$224.51M2.5836,329 shs807,542 shsGERNGeron$1.44+5.9%$1.31$1.04▼$2.01$872.47M0.614.06 million shs11.31 million shsIRWDIronwood Pharmaceuticals$4.38+1.2%$3.84$0.67▼$5.78$706.04M0.22.27 million shs2.99 million shsRIGLRigel Pharmaceuticals$40.26+4.0%$31.74$18.24▼$52.24$716.40M1.14346,095 shs378,419 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXSCodexis+7.69%+14.16%+3.91%+34.34%-3.62%GERNGeron+5.88%+10.77%+23.08%-17.24%+1.05%IRWDIronwood Pharmaceuticals+1.15%+1.86%+32.33%+26.59%+491.89%RIGLRigel Pharmaceuticals+3.98%+3.13%+34.51%+40.13%+112.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXSCodexis 2.00Hold$5.0087.97% UpsideGERNGeron 2.00Hold$2.5073.61% UpsideIRWDIronwood Pharmaceuticals 2.71Moderate Buy$6.2342.31% UpsideRIGLRigel Pharmaceuticals 2.33Hold$54.5035.37% UpsideCurrent Analyst Ratings BreakdownLatest CDXS, GERN, RIGL, and IRWD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026IRWDIronwood Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/23/2026GERNGeron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/17/2026CDXSCodexis Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/2/2026RIGLRigel Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$57.005/26/2026GERNGeron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026CDXSCodexis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026RIGLRigel Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$57.005/13/2026RIGLRigel Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$69.00 ➝ $81.005/8/2026CDXSCodexis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/7/2026RIGLRigel Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/7/2026RIGLRigel Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$71.00 ➝ $69.00(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXSCodexis$70.39M3.44N/AN/A$0.56 per share4.75GERNGeron$183.88M5.02N/AN/A$0.35 per share4.11IRWDIronwood Pharmaceuticals$296.15M2.41$0.26 per share16.82($1.61) per share-2.72RIGLRigel Pharmaceuticals$294.28M2.53$7.01 per share5.74$21.57 per share1.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXSCodexis-$43.97M-$0.37N/AN/AN/A-40.97%-68.09%-23.72%8/12/2026 (Estimated)GERNGeron-$83.50M-$0.11N/A14.40N/A-35.48%-23.31%-10.08%8/5/2026 (Estimated)IRWDIronwood Pharmaceuticals$24.02M$0.607.30N/AN/A28.26%-39.65%26.54%8/6/2026 (Estimated)RIGLRigel Pharmaceuticals$367.02M$18.722.1512.02N/A121.50%47.99%32.40%8/4/2026 (Estimated)Latest CDXS, GERN, RIGL, and IRWD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CDXSCodexis-$0.11-$0.10+$0.01-$0.10$14.53 million$15.25 million5/7/2026Q1 2026IRWDIronwood Pharmaceuticals$0.2467$0.24-$0.0067$0.24$92.11 million$106.51 million5/6/2026Q1 2026GERNGeron-$0.03-$0.01+$0.02-$0.01$50.59 million$51.84 million5/5/2026Q1 2026RIGLRigel Pharmaceuticals$0.7950$0.44-$0.3550$0.44$62.40 million$58.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCDXSCodexisN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXSCodexis0.945.365.23GERNGeron0.526.784.96IRWDIronwood PharmaceuticalsN/A1.411.41RIGLRigel Pharmaceuticals0.042.622.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXSCodexis78.54%GERNGeron73.71%IRWDIronwood PharmaceuticalsN/ARIGLRigel Pharmaceuticals66.23%Insider OwnershipCompanyInsider OwnershipCDXSCodexis3.50%GERNGeron1.71%IRWDIronwood Pharmaceuticals9.30%RIGLRigel Pharmaceuticals10.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXSCodexis25090.90 million87.72 millionOptionableGERNGeron70641.52 million630.55 millionOptionableIRWDIronwood Pharmaceuticals220163.06 million147.89 millionOptionableRIGLRigel Pharmaceuticals16018.50 million16.57 millionOptionableCDXS, GERN, RIGL, and IRWD HeadlinesRecent News About These CompaniesRigel Pharmaceuticals, Inc.: Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical OfficerJuly 1, 2026 | finanznachrichten.deRigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical OfficerJuly 1, 2026 | finance.yahoo.comRigel appoints Alison L Hannah as chief medical officerJuly 1, 2026 | msn.comRigel Appoints Board Member Alison L. Hannah, M.D.July 1, 2026 | prnewswire.comInspire Investing LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGLJuly 1, 2026 | marketbeat.comWhy Rigel Pharmaceuticals, Inc.’s (RIGL) Stock Is Up 5.03%June 26, 2026 | aaii.comAFinancial Survey: Alaunos Therapeutics (NASDAQ:TCRT) versus Rigel Pharmaceuticals (NASDAQ:RIGL)June 26, 2026 | americanbankingnews.comKamil Ali-Jackson Sells 2,500 Shares of Rigel Pharmaceuticals (NASDAQ:RIGL) StockJune 25, 2026 | insidertrades.comA Look At The Transformation Around Rigel PharmaceuticalsJune 20, 2026 | seekingalpha.comRigel Expands Oncology Portfolio with VEPPANU Global RightsJune 17, 2026 | tipranks.comThese small-cap healthcare stocks pair revenue growth with attractive valuationsJune 17, 2026 | seekingalpha.comRigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)June 16, 2026 | prnewswire.comInsider Move: Dean Schorno Exercises Options, Realizing $52K At Rigel PharmaceuticalsJune 5, 2026 | benzinga.comThese 10 small-cap U.S. healthcare companies rank among the market's most attractively valued stocksJune 1, 2026 | seekingalpha.comInsider Selling: Rigel Pharmaceuticals (NASDAQ:RIGL) Director Sells 2,500 Shares of StockMay 29, 2026 | insidertrades.comRigel to Present at the Jefferies Global Healthcare ConferenceMay 27, 2026 | prnewswire.comLilly and Rigel Advance RA Pipeline as Key LY3871801 Mid-Stage Trial Reaches CompletionMay 22, 2026 | tipranks.comRigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 CongressMay 21, 2026 | prnewswire.comRigel Pharmaceuticals, Inc. (RIGL) M&A Call - SlideshowMay 20, 2026 | seekingalpha.comRigel Shareholders Approve Equity Plans and Board SlateMay 20, 2026 | tipranks.comRigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, Arvinas - Has The Bull Case Changed?May 14, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDXS, GERN, RIGL, and IRWD Company DescriptionsCodexis NASDAQ:CDXS$2.66 +0.19 (+7.69%) As of 07/6/2026 04:00 PM EasternCodexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Geron NASDAQ:GERN$1.44 +0.08 (+5.88%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$1.43 -0.01 (-0.49%) As of 04:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Ironwood Pharmaceuticals NASDAQ:IRWD$4.38 +0.05 (+1.15%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$4.49 +0.11 (+2.53%) As of 04:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Rigel Pharmaceuticals NASDAQ:RIGL$40.26 +1.54 (+3.98%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$40.49 +0.23 (+0.58%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
